S&P 500

5.667,20

0,64%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 4 5 6 7 8 9 10 11 12 13 14 15 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
03/03/2005	08:00	PR Newswire (US)	Allos Therapeutics Announces $50 Million Financing	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/01/2005	11:00	PR Newswire (US)	Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/01/2005	11:01	PR Newswire (US)	Allos Therapeutics Announces Expansion of ENRICH Trial Into Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/12/2004	11:00	PR Newswire (US)	Allos Therapeutics Licenses New Cancer Compound	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2004	14:38	PR Newswire (US)	Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Sympos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2004	09:00	PR Newswire (US)	Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/11/2004	11:01	PR Newswire (US)	Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2004	19:30	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2004	19:30	PR Newswire (US)	Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/10/2004	11:00	PR Newswire (US)	Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/10/2004	10:00	PR Newswire (US)	Allos Therapeutics to Present at Rodman & Renshaw Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2004	10:00	PR Newswire (US)	Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/10/2004	18:30	PR Newswire (US)	Response at Three-Months Post WBRT Found to be Statistically Significant Predictor of Survival in Largest Ever Randomized Study	NASDAQ:ALTH
04/10/2004	16:30	PR Newswire (US)	Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	17:23	PR Newswire (US)	Allos Therapeutics Receives Orphan Drug Designation From U.S. FDA for EFAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	09:45	PR Newswire (US)	Reminder - Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	08:00	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/07/2004	10:00	PR Newswire (US)	Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2004	10:01	PR Newswire (US)	Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/06/2004	10:00	PR Newswire (US)	Allos to Present at Needham and Company's Third Annual Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/06/2004	10:01	PR Newswire (US)	Data Presented at ASCO Demonstrate That Red Blood Cell Levels of Allos Therapeutics' RSR13 Correlate With Treatment Effect in Pa	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/06/2004	15:05	PR Newswire (US)	Data From Phase 3 Trial of Allos Therapeutics' RSR13 (efaproxiral) Presented at ASCO	NASDAQ:ALTH
06/06/2004	14:23	PR Newswire (US)	Analysis From Phase 3 Trial Suggests That Some Non-Small Cell Lung Cancer Patients With Brain Metastases May Benefit From Allos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/06/2004	10:00	PR Newswire (US)	Allos Therapeutics Files Application for European Marketing Approval of RSR13 (efaproxiral)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/06/2004	11:00	PR Newswire (US)	Federman & Sherwood Announces That a Securities Class Action Lawsuit Was Filed Against Allos Therapeutics, Inc.	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/06/2004	10:00	PR Newswire (US)	Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/05/2004	10:00	PR Newswire (US)	Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
25/05/2004	13:23	PR Newswire (US)	Wolf Haldenstein Adler Freeman and Herz LLP Commences Class Action Lawsuit on Behalf of Allos Therapeutics, Inc. Shareholders	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/05/2004	18:13	PR Newswire (US)	Geller Rudman Announces Class Action Lawsuit Against Allos Therapeutics, Inc. on Behalf of Investors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/05/2004	17:13	PR Newswire (US)	Shareholder Class Action Filed Against Allos Therapeutics, Inc. by the Law Firm of Schiffrin & Barroway, LLP	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)